CRISPR Therapeutics AG
NasdaqGM:CRSP
Sector
Location
Market Cap
USD 4.98 B
Share Price
USD 57.68
Avg Daily Volume
3,092,088
Change (1 day)
-2.27%
Change (1 year)
2.25%
Change (YTD)
46.54%
CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2024: USD 14.71 M
CRISPR Therapeutics AG Accounts Payable is USD 14.71 M for the year ending December 31, 2024, a -61.44% change year over year. Accounts payable are amounts owed by the company to suppliers or vendors for goods or services received but not yet paid.
-
CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2023 was USD 38.15 M, a 39.08% change year over year.
-
CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2022 was USD 27.43 M, a 85.12% change year over year.
-
CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2021 was USD 14.82 M, a 62.92% change year over year.
-
CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2020 was USD 9.09 M, a 52.99% change year over year.
StockViz
Competitors
Pacific Biosciences of California, Inc.
USD 1.49
PACB
-0.05
-3.25%
Intellia Therapeutics, Inc.
USD 12.33
NTLA
-0.17
-1.36%
Teladoc Health, Inc.
USD 7.40
TDOC
-0.13
-1.73%
Editas Medicine, Inc.
USD 2.52
EDIT
-0.07
-2.70%
Beam Therapeutics Inc.
USD 20.15
BEAM
+0.22
1.10%
Ginkgo Bioworks Holdings, Inc.
USD 12.88
DNA
-0.04
-0.31%
Vertex Pharmaceuticals Incorporated
USD 469.16
VRTX
+0.75
0.16%
Key Data
| Date | Accounts Payable | Short-Term Debt | Long-Term Debt | Total Liabilities |
|---|
Competitors
Pacific Biosciences of California, Inc.
USD 1.49
PACB
-0.05
-3.25%
Intellia Therapeutics, Inc.
USD 12.33
NTLA
-0.17
-1.36%
Teladoc Health, Inc.
USD 7.40
TDOC
-0.13
-1.73%
Editas Medicine, Inc.
USD 2.52
EDIT
-0.07
-2.70%
Beam Therapeutics Inc.
USD 20.15
BEAM
+0.22
1.10%
Ginkgo Bioworks Holdings, Inc.
USD 12.88
DNA
-0.04
-0.31%
Vertex Pharmaceuticals Incorporated
USD 469.16
VRTX
+0.75
0.16%